Evidence map›Paper›PMID 39928830›Full record

ArticleMedicine2025

Refractory immune thrombocytopenia treated with low-dose decitabine combined with recombinant human thrombopoietin or eltrombopag: Two case reports.

Yuxia Jiang, Yani Xu, Haiying Wu, Minxia He, Huifang Jiang, Xiaofeng Xu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuxia JiangDepartment of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou, P.R. China.
Yani XuDepartment of Rehabilitation, Zhejiang Aged Care Hospital, Hangzhou, Zhejiang, P.R. China.ORCID 0000-0002-7467-0256
Haiying WuDepartment of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou, P.R. China.
Minxia HeDepartment of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou, P.R. China.
Huifang JiangDepartment of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou, P.R. China.
Xiaofeng XuDepartment of Hematology, Hangzhou Red Cross Hospital, Hangzhou, Zhejiang, P.R. China.

Funding

Hangzhou Municipal Health Commission A20210210
6 · The paper itself

Abstract

rationaleImmune thrombocytopenia (ITP) is an autoimmune-mediated disorder caused by antibody-mediated platelet destruction and impaired platelet production by megakaryocytes. Treating refractory ITP remains a significant challenge. PATIENT CONCERNS AND DIAGNOSES: We report 2 patients with refractory ITP. INTERVENTIONS AND OUTCOMES: Two patients received low-dose decitabine combined with recombinant human thrombopoietin or eltrombopag. Platelet counts in both patients increased to within the normal range. LESSONS: Low-dose decitabine combined with recombinant human thrombopoietin or eltrombopag may exert a synergistic effect in the treatment of refractory ITP.

Indexed as

AzacitidineBenzoatesDecitabineHydrazinesPurpura, Thrombocytopenic, IdiopathicPyrazolesThrombopoietinDrug Therapy, CombinationHumansPlatelet CountRecombinant ProteinsAzacitidineBenzoatesDecitabineeltrombopagHydrazinesPyrazolesRecombinant ProteinsThrombopoietin

Identifiers

PMID39928830
PMCPMC11813053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.